Role of AHT#1 food supplement in symptom control of IBS-D
Research type
Research Study
Full title
Role of AHT#1 (Curcumin/green tea/vitamin D) food supplement on symptom control in diarrhoea predominant irritable bowel syndrome (IBS-D) as assessed by the IBS Severity Scoring System (IBS-SSS)
IRAS ID
243905
Contact name
Anton Emmanuel
Contact email
Sponsor organisation
University College London
ISRCTN Number
ISRCTN15346028
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
IBS is a common bowel complaint and so far there is no single long lasting cure for the symptoms such as bloating and diarrhoea. IBS has no attributable mortality, but it is important due to the effect that symptoms have on quality of life (QoL) and as consequence a big cost for the public service.
The research will be undertaken to test whether the food supplement AHT#1, helps people with IBS and bloating. The supplement contains curcumin, vitamin D3 and green tea.
Published evidence suggest that these supplements individually can be effective in IBS and also inflammatory bowel disease, so therefore this study is assessing benefit of combination supplement in IBS symptom severity score.
Adult patients diagnosed with IBS type D (diarrhea predominant) be recruited by doctors in the gastroenterology clinicAfter written consent the patients will receive one pot of product in clinic and a 1 page paper form called an IBS-Severity Scoring System (IBS-SSS) . The patient will complete the IBS-SSS survey in clinic and return to the research Doctor.
The patient takes 2 capsules of AHT#1 a day for 28 days and complete the bowel diary. The patient will have a follow-up clinic appointment at 28 days for review and to check the supplement pack regarding compliance (number of capsules left) and to return the bowel diary.
The patient may choose to take the product for 56 more days and will be given the supply in clinic. They return 2 months later to clinic and complete the final IBS-SSS questionnaire prior to the appointment. The supplement pack shall be checked for compliance. Should the patient still be gaining benefit, they can request 3 month’s supply of free product. The study will be end 4 months from the recruitment of the last patient.REC name
London - Brent Research Ethics Committee
REC reference
18/LO/2079
Date of REC Opinion
21 Mar 2019
REC opinion
Further Information Favourable Opinion